About Kinaset Therapeutics
Kinaset Therapeutics develops inhaled therapeutics for respiratory diseases. The company's lead candidate, KN-002, is an anti-inflammatory treatment for severe asthma patients. Kinaset Therapeutics licenses KN-002 and is responsible for its development and commercialization.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-B+
Global Headquarters
Boston, United States
Year Founded
2020
Team Size
1-10
Tracked Since
Sep 29, 2026
Web & Domain Identity
Official Website
kinasettherapeutics.com
Domain Registered Date
May 1, 2020
Social & Network Presence
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Raised $103,000,000 · Series-B+
fundraisingfox.com
- Capital Raise
Raised $40,000,000 · Series-A
- Milestone
X account created (@KinasetT)
81 followers
- Milestone
Website domain registered
kinasettherapeutics.com
- Milestone
Company founded
Boston, United States
Investors & Backers
5AM Ventures
Atlas Venture
EQT Life Sciences
Forge Life Science Partners
Gimv
Pictet Alternative Advisors
RA Capital Management
Schroders Capital
Sixty Degree Capital
Vivo Capital
Willett Advisors LLC
Funding History
Series-B+
· Jan 9, 2026
$103,000,000 fundraisingfox.com
Series-A
· Nov 30, 2020
$40,000,000 Source
Founders & Leadership
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026